Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.5350
-0.0065 (-1.20%)
At close: Feb 11, 2026, 4:00 PM EST
0.5700
+0.0350 (6.54%)
After-hours: Feb 11, 2026, 7:56 PM EST
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change
-9
Growth
-12.33%
Revenue / Employee
$496,938
Profits / Employee
-$913,891
Market Cap
36.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 64 | -9 | -12.33% |
| Mar 31, 2024 | 56 | -33 | -37.08% |
| Dec 31, 2023 | 73 | -16 | -17.98% |
| Sep 30, 2023 | 81 | -8 | -8.99% |
| Jun 30, 2023 | 84 | 6 | 7.69% |
| Mar 31, 2023 | 89 | 11 | 14.10% |
| Dec 31, 2022 | 89 | 15 | 20.27% |
| Mar 31, 2022 | 78 | 21 | 36.84% |
| Dec 31, 2021 | 74 | 17 | 29.82% |
| Sep 30, 2021 | 69 | - | - |
| Jun 30, 2021 | 66 | - | - |
| Mar 31, 2021 | 57 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Generation Bio Co. | 115 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| Veru Inc. | 20 |
XLO News
- 4 hours ago - Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript - Seeking Alpha
- 3 months ago - Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewsWire